Substitute for PTO-1390 (Rev. 07-2005) "1 Approved for use through 3/31/2007. OM	ransmittal Letter to the United States Designated Electric 1B 0651-0021	RECEPTION NOVEL 2015 C. 371"					
U. S. PAT	ENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 21431P					
TRANSMITTAL LETTER							
DESIGNATED/ELECTE	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
CONCERNING A FILIN	10/558931						
INTERNATIONAL APPLICATION NO.		PRIORITY DATE CLAIMED					
PCT/US2004/017111	02 June 2004	06 June 2003					
TITLE OF INVENTION FUSED INDOLES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES							
APPLICANT(S) FOR DO/EO/US	1: 5 5 5						
Scott D. Edmondson, Anthony Mastra							
Applicant herewith submits to the other information:	United States Designated/Elected Off	fice (DO/EO/US) the following items and					
1. X This is a FIRST submission	of items concerning a filing under 35 U	J.S.C. 371.					
2. This is a SECOND or SUBS	SEQUENT submission of items concer	ning a filing under 35 U.S.C. 371.					
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.							
4. X The US has been elected (PC	CT Article 31).						
5. A copy of the International A							
a. is attached hereto (rec							
b. has been communicat							
c. X is not required, as the	application was filed in the United Sta	tes Receiving Office (RO/US).					
~ ~ ~ ~ ~ ~	tion of the International Application as	filed [35 U.S.C. 371(c)(2)].					
a. is attached hereto	1 14 1 1 25 11 0 0 154(1)(4)						
b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau).							
b. have been communicated by the International Bureau.							
c. have not been made; l	c. have not been made; however, the time limit for making such amendments has NOT expired.						
d. have not been made a	d. have not been made and will not be made.						
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].							
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].							
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].							
Items 11 to 20 below concern other	document(s) or information include						
	statement under 37 CFR 1.97 and 1.98.						
12. An assignment document for is included.	recording. A separate cover sheet in c	ompliance with 37 CFR 3.28 and 3.31					
13. A preliminary amendment.							
14. An Application Data Sheet u	4. An Application Data Sheet under 37 CFR 1.76.						
15. A substitute specification.							
16. A power of attorney and/or c	hange of address letter.	·					
17. A computer-readable form of	7. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.						
8. A second copy of the published International Application under 35 U.S.C.154(d)(4).							
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).							
20. Other items or information:							

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(Do/ED/US) Concerning a Submission Under 35 U.S.C. 371"

Approved for use through 3/31/2007. OMB 0651-0021

U.S. APPLICATION N	O. (If kno	wn, see 37 CFI	R 1.5)	INTERN	ATIONAL APPLICATION NO.			ATTORNEY'S DOC	KET NUMBER
10	10/558931 PCT/US2004/017111						21431P		
The following				1				CALCULATIONS	PTO USE ONLY
21. A Basic national fee					\$300	\$300.00			
22. X Examination fee (37 CFR 1.492(c))									
					preliminary examination report PCT Article 33(1)-(4)		\$0		
1								\$0.00	
23. X Search fee	(37 CFI	R 1.492(b))							
					inary examination report prep 33(1)-(4)				
					onal application to the USPT				
International Searchin	g Autho	rity	ISA other	than the	US and provided to the Office		\$100	\$0.00	
							\$400		
All other situations									
Additional for 6	iG	ination and di	muinas fil	ad in man	TOTAL OF			\$300.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
Total Sheets		Sheets Number		of each additional 50 or fraction (round up to a whole number)			RATE		
38 - 100 =	0	/50	0	=	0	х	\$250.00	\$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].							claimed	3 or	
CLAIMS		NUMBER	FILED		NUMBER EXTRA		RATE	2	
Total Claims			23	- 20 =	3	х	\$50.00	\$150.00	
Independent Claims			1	- 3 =	0	Х	\$200.00	\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00					\$360.00				
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) =						\$450.00			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).									
TOTAL NATIONAL FEE =						\$450.00			
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property.									
					TOTAL FEES ENCLO	SED	=	\$450.00	
								Amount to be	
							refunded:		
					Amount to be				
charged:									
a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 13-2755 in the amount of \$450.00 to cover the above fees.									
A duplicate copy of this sheet is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:									
Customer No. 000210									
MERCK & CO., INC. Patent Department, RY60-30						Z Church			
P.O. Box 2000 SIGNATURE						- comer			
126 East Lincoln Avenue									
Kanway, New Je	Rahway, New Jersey 07065-0970 Philippe L. Durette			L. Durette					
NAME DATE: November 30, 2005									
PHONE #: (732) 594-4568									
PHONE #: (732) 394-4306 REGISTRATION NUMBER									

10/558931

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES 30 NOV 2005 DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Serial No.	PCT/US04/17111					
Case Docket No.:	21431P 02 June 2004					
International Filing Date:						
Priority Date:	06 June 2003					
Title:	FUSED INDOLES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES					
Inventors:	Scott D. Edmondson, Anthony Mastracchio, Emma R. Parmee					

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT November 30, 2005

EXPRESS MAIL NO. EV 660609095 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY